TAIGALOR ® Lornoxicam

TAIGALOR ® is a drug based on Lornoxicam

THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications TAIGALOR ® Lornoxicam

TAIGALOR ® is used as an anti-inflammatory-analgesic in the symptomatic treatment of pain present during inflammatory diseases of a rheumatic and degenerative nature.

Mechanism of action TAIGALOR ® Lornoxicam

TAIGALOR ®, a non-steroidal anti-inflammatory drug known for its excellent anti-inflammatory and analgesic properties, is a medicine based on Lornoxicam, an active ingredient belonging to the recent category of oxicam.

Taken orally it is rapidly absorbed from the intestinal mucosa, reaching the peripheral districts linked to plasma proteins, with a very close bioavailability 100% of the total dose taken.

Concentrating predominantly at the synovial level, Lornoxicam is able to inhibit cyclooxygenases 2 with high selectivity, thus reducing the production of chemical mediators with pro-inflammatory activity known as prostaglandins.

The inhibition of these mechanisms takes the form of:

in the anti-inflammatory action, guaranteed by the reduced recruitment of inflammatory cells and by the control of vascular permeability;
in the pain-relieving action, mediated by the reduction of bradykinin production, responsible for activating peripheral nociceptive endings;
in the antioxidant action, useful in combating tissue damage induced by reactive oxygen species and various proteolytic enzymes.

Following a hepatic metabolism, characterized by intense hydroxylation processes, the inactive catabolites of lornoxicam are mainly excreted in the urine.

Studies carried out and clinical efficacy

1. LORNOXICAM IN DENTAL PRACTICE

Med Princ Pract. 2011; 20 (5): 470-6. Epub 2011 Jul 11.

Work demonstrating that taking Lornoxicam before extraction of the third molar can be effective in reducing pain associated with surgery without clinically relevant side effects.

2 . LORNOXICAM IN THE CONTROL OF PAIN IN PATIENTS WITH LUMBOSCIATALGIA

Int J Clin Pract. 2009 Nov; 63 (11): 1613-21.

A randomized double-blind study demonstrating that taking Lornoxicam 8-24 mg a day may be effective in improving the painful symptoms of sciatic loin.

3. SAFETY AND EFFICIENCY OF LORNOXICAM IN RHEUMATOID ARTHRITIS

Minerva Med. 2002 Aug; 93 (4): 315-20.

Italian study lasting one year to evaluate the effectiveness but above all the long-term safety profile of Lornoxicam, when used in patients with rheumatoid arthritis.

The data demonstrate the excellent tolerability of the therapy even in the face of good therapeutic efficacy.

Method of use and dosage

TAIGALOR ®

8 mg Lornoxicam coated tablets.

Treatment with painful states during rheumatic diseases with TAIGALOR ® should be supervised by a specialist doctor.

Generally it could be useful to define a dosage scheme characterized by an attack phase, consisting of the maximum administration of 32 mg / day of Lornoxicam followed by a maintenance phase consisting of the intake of 8 mg / day.

A further adjustment of the dosage would be recommended for elderly patients or those suffering from liver and kidney diseases.

Warning TAIGALOR ® Lornoxicam

Given the potential side effects and the many contraindications associated with Lornoxicam therapy, you should consult your doctor before taking TAIGALOR ®.

In fact, medical supervision is necessary both in the definition of the ideal dosage and in the monitoring of potential side effects and the effectiveness of the therapy.

The doctor should also pay particular attention to the therapy in progress in patients suffering from cardiovascular, coagulative, renal, hepatic, allergic and gastrointestinal diseases due to the greater susceptibility to the side effects related to the use of non-steroidal anti-inflammatory drugs.

The appearance of undesired effects should therefore alarm the patient, who after consulting his doctor could seriously consider the possibility of suspending the treatment.

Lornoxicam intake may alter some blood chemistry parameters, masking existing pathological patterns.

TAIGALOR ® contains lactose, therefore its intake is contraindicated in patients with lactose intolerance, glucose-galactose malabsorption syndrome and lactase enzyme deficiency.

PREGNANCY AND BREASTFEEDING

Note the importance of prostaglandins in correctly guiding the process of cellular differentiation during embryonic and fetal development and given the different side effects of fetal health induced by NSAIDs during pregnancy it is necessary to extend the contraindications to use of TAIGALOR ® also to pregnancy and subsequent breastfeeding period.

Interactions

The high systemic absorption of Lornoxicam and the intense hepatic metabolism to which it is subjected greatly increase the risks associated with the simultaneous intake of other active ingredients.

In order to limit the possible variations of the therapeutic properties and the safety profile of the Lornoxicam, it would be appropriate to pay particular caution to the simultaneous assumption of:

Oral anticoagulants and inhibitors of serotonin reuptake, due to the increased risk of bleeding;
Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and cyclosporin, due to their ability to enhance the hepatotoxic and nephrotoxic effects of Lornoxicam;
Non-steroidal anti-inflammatory drugs and corticosteroids due to damage to the gastro-intesintale mucosa;
Lithium, given the increased toxic effects of the same;
Cimetidicin, able to increase plasma concentrations of Lornoxicam, thus increasing the incidence of side effects.

Contraindications TAIGALOR ® Lornoxicam

The use of TAIGALOR ® is contraindicated in case of hypersensitivity to the active ingredient or to one of its excipients or to chemically and functionally related active ingredients, angioedema, peptic ulcer, history of intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same pathologies, cerebrovascular bleeding, hemorrhagic diathesis or concomitant anticoagulant therapy, renal and hepatic failure.

Undesirable effects - Side effects

Although TAIGALOR ® therapy is generally well tolerated, according to various experimental evidence and routine clinical practice, it should be remembered that taking Lornoxicam may increase the incidence of:

Gastrointestinal symptoms such as heartburn, gastralgia, nausea and vomiting, constipation and in severe cases ulcers and bleeding;
Nervous symptoms such as hearing and sight disorders, headache, insomnia, drowsiness, confusion and tremors;
Dermatological reactions characterized by erythema, rash, urticaria and in more serious cases, bullous diseases;
Cardiovascular symptoms such as hypertension, sloping edema and heart failure.

However, the incidence and severity of these adverse reactions is proportional to the dose used and the duration of treatment.